Triumvira Immunologics develops T cell therapies using its proprietary T cell Antigen Coupler (TAC) platform, which enhances T cell activation to target and destroy cancer cells across various tumor types. This approach addresses the challenge of treating difficult-to-manage cancers by leveraging the body's natural immune response for improved therapeutic outcomes.
Funding
$168M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers are difficult to treat due to their ability to evade the body's natural immune response. Current cancer therapies often fail to provide long-term remission, especially in patients with solid tumors or advanced disease. This highlights the need for innovative approaches that can effectively harness the immune system to target and eliminate cancer cells.
Solution
Triumvira Immunologics develops T cell therapies using its proprietary T cell Antigen Coupler (TAC) platform to enhance T cell activation and target cancer cells. The TAC technology co-opts natural T cell biology, enabling T cells to locate and destroy tumor cells through natural activation and controlled anti-tumor responses. By enabling T cells to target cancer cells using different antigens, TAC can be applied across a wide range of liquid and solid tumors. The company is developing multiple TAC-based therapeutic candidates using both autologous and allogeneic manufacturing approaches.
Target Audience
The primary target audience includes patients with difficult-to-treat cancers, oncologists, and medical researchers focused on developing novel immunotherapies.
Features
- Proprietary T cell Antigen Coupler (TAC) platform enhances T cell activation.
- TAC technology co-opts natural T cell biology for targeted tumor cell destruction.
- Applicable across a wide range of liquid and solid tumors by targeting different antigens.
- Development of multiple TAC-based therapeutic candidates.
- Utilizes both autologous and allogeneic manufacturing approaches.
- Employs advanced manufacturing technologies for optimum product quality.